Skip to main content

Wanbury Gets US FDA OAI Classification For Tanuku Plant; Business Continuity Unaffected

The US FDA classified the inspection of Wanbury's Tanuku API manufacturing unit as Official Action Indicated (OAI). While Tanuku contributes around 70% of total company revenue, direct US revenue accounts for only 6%, and existing product shipments will continue without interruption.

Author Image
Sahi Markets
Published: 16 Nov 2026, 03:06 PM IST (1 hour ago)
Last Updated: 16 Nov 2026, 03:06 PM IST (1 hour ago)
2 min read
Reviewed by Arpit Seth

Market snapshot: Wanbury Limited has received an Official Action Indicated classification from the US FDA following an inspection at its active pharmaceutical ingredient facility in Tanuku, Andhra Pradesh. The company confirmed that business operations and existing customer product supplies from the unit remain unaffected.

Data Snapshot

  • US FDA inspection at the Tanuku API plant conducted during July 2026 resulted in an Official Action Indicated (OAI) classification.
  • The Tanuku, Andhra Pradesh plant accounts for approximately 70% of Wanbury's overall revenue contribution.
  • The US market direct exposure stands at 6% of company revenue, limiting financial risk from potential US market supply delays.

What's Changed

  • Regulatory status for the Tanuku site transitioned from Form 483 with six observations issued in July 2026 to Official Action Indicated (OAI) classification in November 2026.
  • Future US drug applications (ANDAs) will be routed through the company's US FDA-approved Patalganga facility to insulate growth pipeline.

Key Takeaways

  • US FDA issued an Official Action Indicated (OAI) outcome for Wanbury's primary API site in Tanuku.
  • Current customer orders and ongoing product supplies from the facility are not impacted by the classification.
  • Direct revenue risk is contained due to the US market representing only 6% of total company sales.
  • Patalganga facility will serve as the alternative manufacturing platform for new US regulatory product filings.

SAHI Perspective

Wanbury's OAI classification at its principal API manufacturing plant presents a regulatory challenge, but the near-term commercial fallout is mitigated by low direct US market exposure of 6%. Operative continuity for existing commercial products ensures stable baseline cash flows while management remediates compliance issues with the US FDA.

Market Implications

The OAI classification may temporarily cap valuation multiples for the stock until regulatory resolution is achieved. However, non-US export markets and domestic formulation channels remain unhindered, supporting baseline revenues.

Trading Signals

Market Bias: Neutral

While regulatory actions introduce short-term uncertainty, existing product supplies from Tanuku are unaffected and US revenue exposure is restricted to 6%, balancing structural operating risk.

Underweight: API Exporters with US Regulatory Exposure

Trigger Factors:

  • Receipt of US FDA re-inspection schedule or Warning Letter status
  • Filing of new ANDA approvals via Patalganga facility

Time Horizon: Near-term (0-3 months)

Industry Context

US FDA regulatory oversight of active pharmaceutical ingredient plants in India remains strict. An OAI status typically requires complete remediation of plant procedures and compliance controls before new product approvals can proceed from the affected site.

Key Risks to Watch

  • Potential escalation to a US FDA Warning Letter or Import Alert if remediation measures are deemed inadequate.
  • Delay in launching new products in the US market sourced from the Tanuku manufacturing facility.

Recent Developments

On October 30, 2026, Wanbury's Tanuku plant received a Good Manufacturing Practice (GMP) Compliance Certificate from Australia's Therapeutic Goods Administration (TGA) valid through December 2028. Additionally, on October 19, 2026, the site received the Best Employer Award from the Andhra Pradesh State Government.

Closing Insight

Wanbury's focus on maintaining business continuity while leveraging its Patalganga facility provides immediate commercial protection while compliance remediation at Tanuku proceeds.

High Performance Trading with SAHI.

Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.

Open Free Account

Frequently Asked Questions (FAQs)

All topics

Add Sahi as a Preferred Source on Google

Click the link, confirm the box next to sahi.com is checked — ignore any other results.